Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.
暂无分享，去创建一个
M. Liedtke | H. Kantarjian | G. Martinelli | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | E. Vandendries | N. Gökbuget | R. Cassaday | D. Marks | M. Stelljes | Tao Wang | Akil A. Merchant